| Literature DB >> 35625570 |
Aditi Chopra1, Thilini N Jayasinghe2,3, Joerg Eberhard2,3.
Abstract
Advanced glycation end-products (AGEs) are heterogeneous compounds formed when excess sugars condense with the amino groups of nucleic acids and proteins. Increased AGEs are associated with insulin resistance and poor glycemic control. Recently, inflamed periodontal tissues and certain oral bacteria were observed to increase the local and systemic AGE levels in both normoglycemic and hyperglycemic individuals. Although hyperglycemia induced AGE and its effect on the periodontal tissues is known, periodontitis as an endogenous source of AGE formation is not well explored. Hence, this systematic review is aimed to explore, for the first time, whether inflamed periodontal tissues and periodontal pathogens have the capacity to modulate AGE levels in individuals with or without T2DM and how this affects the glycemic load. Six electronic databases were searched using the following keywords: (Periodontitis OR Periodontal disease OR Periodontal Inflammation) AND (Diabetes mellitus OR Hyperglycemia OR Insulin resistance) AND Advanced glycation end products. The results yielded 1140 articles, of which 13 articles were included for the review. The results showed that the mean AGE levels in gingival crevicular fluid was higher in individuals with diabetes mellitus and periodontitis (521.9 pg/mL) compared to healthy individuals with periodontitis (234.84 pg/mL). The serum AGE levels in normoglycemic subjects having periodontitis was higher compared to those without periodontitis (15.91 ng/mL vs. 6.60 ng/mL). Tannerella forsythia, a common gram-negative anaerobe periodontal pathogen in the oral biofilm, was observed to produce methylglyoxal (precursor of AGE) in the gingival tissues. Increased AGE deposition and activate of AGE receptors was noted in the presence of periodontitis in both normoglycemic and hyperglycemic individuals. Hence, it can be concluded that periodontitis can modulate the local and systemic levels of AGE levels even in absence of hyperglycemia. This explains the bidirectional relationship between periodontitis and development of prediabetes, incident diabetes, poor glycemic control, and insulin resistance.Entities:
Keywords: advanced glycation end-products; biomolecules; diabetes mellitus; hyperglycemia; inflammation; oral health; oxidative stress; periodontitis
Mesh:
Year: 2022 PMID: 35625570 PMCID: PMC9138899 DOI: 10.3390/biom12050642
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1Schematic representation explaining how periodontitis can increase AGE levels.
Search strategy for different databases for including articles for the title and abstract screening.
| S/No | Database | Search String Used | Total Number of Articles |
|---|---|---|---|
| 1. |
| [“periodontitis” OR “periodontal disease” OR “Chronic periodontitis” OR “periodontal Inflammation”) AND (“diabetes” OR “diabetes mellitus” OR “Type 2 DM” OR “Type 2 diabetes mellitus” OR “non-insulin dependent diabetes mellitus” OR “Hyperglycemia” OR Insulin resistance)) AND (“Advanced glycation end products” OR “Advanced glycosylation end products” OR “Millard Reaction” OR “carboxymethylysine” OR “Pentosidine”) |
|
| 2. |
| “Periodontitis” OR “Periodontal disease” OR “Chronic periodontitis” OR “Periodontal Inflammation”) AND (“Diabetes” OR “Diabetes mellitus” OR “Type 2 DM” OR “Type 2 diabetes mellitus” OR “non-insulin-dependent diabetes mellitus” OR “Hyperglycemia” OR “Insulin resistance”) AND (“Advanced glycation end product” OR “Advanced glycosylation end products” OR “Millard Reaction” OR “carboxymethylysine” OR “Pentosidine”) |
|
| 3. |
| TI = (“Periodontitis” OR “periodontal disease” OR “Chronic periodontitis” OR “periodontal Inflammation”) AND (“diabetes” OR “diabetes mellitus” OR “Type 2 DM” OR “Type 2 diabetes mellitus” OR “non-insulin dependent diabetes mellitus” OR “Hyperglycemia” OR Insulin resistance)) AND (“Advanced glycation end products” OR “Advanced glycosylation end products” OR “Millard Reaction” OR “carboxymethylysine” OR “Pentosidine”) |
|
| 4. |
| TI (Periodontitis OR periodontal disease OR Chronic periodontitis OR periodontal Inflammation AND Diabetes OR diabetes mellitus OR Type 2 DM OR Type 2 diabetes mellitus OR non-insulin dependent diabetes mellitus OR Hyperglycemia OR Insulin resistance AND Advanced glycation end products OR Advanced glycosylation end products OR Millard Reaction OR carboxymethylysine OR Pentosidine) |
|
| 5. |
| Periodontitis OR periodontal disease OR Chronic periodontitis OR periodontal Inflammation in Title Abstract Keyword AND Diabetes OR diabetes mellitus OR Type 2 DM OR Type 2 diabetes mellitus OR non-insulin dependent diabetes mellitus OR Hyperglycemia OR Insulin resistance in Title Abstract Keyword AND Advanced glycation end products OR Advanced glycosylation end products OR Millard Reaction OR carboxymethylysine OR Pentosidine in Title Abstract Keyword—with Publication Year from 2000 to 2020, in Trials |
|
| 6. |
| Periodontitis and advanced glycation End products |
|
|
|
|
Figure 2Prisma flow diagram.
Characteristics of the included studies.
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
| ||||||
|
| ||||||||||
|
| Male:Female: 1.2:1.0. | Presence or absence of BOP with CP: CAL > 5 mm. | World Health Organization (not specified) | ELISA | DM + PD | 2.5 ± 0.8 mU/mL | - | - | - | 3.3 ± 4.8 |
| DM + no PD | 2.6 ± 1.0 mU/mL | - | - | - | 1.4 ± 2.8 | |||||
|
| Only male patients. Age range: 35–55 years | Periodontitis: CAL ≥ 5 mm | HbA1c > 9% | ELISA | DM + PD | 26.92 ng/mL | - | 5.58 ± 0.48 | 5.57 ± 0.55 | 73.01 ± 14.60 |
| No DM + PD | 15.91 ng/mL | - | 5.24 ± 0.64 | 5.14 ± 0.41 | 70.40 ± 9.27 | |||||
| No DM + No PD | 6.60 ng/mL | - | - | - | - | |||||
|
| Only male patients (100 males in each group). Mean age: 42.9 ± 9.9 years |
Periodontitis group: ≥5 mm PD along with CAL ≥ 3 mm, and BOP ≥ 30% of their surfaces. | Normoglycemic patients | ELISA/Immunohistochemistry/spectrophotometry | No DM + PD | sRAGE levels = 0.95 ± 0.43 ng/mL | 4.5-fold increase in the expression of cRAGE and 2.3 folds increase in AGER1 expression in periodontitis-affected sites compared to control | 3.0 ± 1.0 | 2.3 ± 1.6 | 37.7 ± 26.6 |
| No DM + No PD | sRAGE = 1.17 ± 0.40 ng/mL | - | - | - | ||||||
|
| Male: Female: | Periodontitis group: CPI score of 0, 1 or 2: Non periodontitis group | Individuals with DM and healthy controls | ELISA | DM + PD | sRAGE with the G82G genotype in plasma: | - | - | - | - |
| DM + NO PD | sRAGE in plasma with the G82G genotype: 991.3 ± 507.6 pg/mL | - | - | - | - | |||||
| No DM + | sRAGE in plasma with the G82G genotype: 845.1 ± 335.0 pg/mL | - | - | - | - | |||||
| No DM + No PD | sRAGE in plasma with the G82G genotype: 890.5 ± 326.4 pg/mL | - | - | - | ||||||
|
| ||||||||||
|
| Male:Female: 1:1 | Periodontitis group: CAL ≥ 3 mm, GI > 1, PD ≥ 5 mm, and radiographic bone loss. | DM = HbA1c ≤ 7% (minimum 5 years of DM) | ELISA | DM + PD | - | sRAGE (GCF): 442.425 ± 72.88 pg/mL | 2 ± 0.655 | 5.60 ± 0.88 | - |
| DM + no PD | - | sRAGE (GCF): 536.88 ± 78.83 pg/mL | 6.60 ± 1.27 | 0 | - | |||||
| No DM + PD | - | sRAGE (GCF): (607.56 ± 84.40 pg/mL | 6.15 ± 1.09 | 5.05 ± 1.67 | - | |||||
| No DM + No PD | - | sRAGE (GCF): 690.74 ± 68.38 pg/mL | 2 ± 0.66 | 0 | - | |||||
|
| DM + PD = Male:Female: 5.4:1.0 | Periodontitis group: Presence of BOP, Pl, PD ≥ 4 mm, CAL ≥ 3 mm, and MBL ≥ 3 mm at six sites per tooth at least 30% of sites. | Normoglycemic→ HbA1c levels of ≤5.6% | GCF | DM + PD | 521.9 pg/mL | - | 49.2% ( | - | 5.2% (3.5 to 5.8%) ( |
| No DM + PD | 234.84 pg/mL | - | 34.4% ( | - | 3.3% (3 to 5%) | |||||
| No DM + No PD | 87.2 pg/mL | - | 0% ( | - | 0.8% (0 to 1.5%) | |||||
|
| Male: Female ratio: | Periodontitis group: minimum of four | Normoglycemic patient (not mentioned about the glycemic control) | GCF | PD with disease sites | MG levels: 200.7 ± 243.1 pmol/sites | - | Mean PD with sites from which MG was collected: 5.77 ± 0.7 mm | 3.27 ± 0.8 mm | 24 ± 13 |
| PD with Healthy sites | MG levels: 140.9 ± 236.6 picomoles/sites | - | Whole mouth PD with sites from which MG was collected: 2.77 ± 0.6 mm | 3.27 ± 0.8 mm | ||||||
| Healthy controls | Mean MG levels: 11.5 ± 4.4 | - | Mean PD with sites from which was collected: 2.77 ± 0.5 mm | 2.07 ± 0.4 | 10 ± 10 | |||||
|
| ||||||||||
|
| Male:female: Not mentioned | Generalized periodontal disease: CAL 30% with BOP | Fasting blood glucose levels of <126 mg/dl as reported by the patient | Immunohistochemistry, | DM + PD | The RAGE increased in the spinous and basal layer of the inflamed gingival epithelium in subjects with and without T2DM having periodontitis. Approximately 50% increase in RAGE mRNA was noted in the gingiva of patients with DM with periodontitis compared having healthy controls with periodontitis ( | ||||
| No DM + PD | ||||||||||
|
| Male: Female: Not mentioned | Periodontal disease consisting of a PD of ≥ 3 mm and CAL of ≥6 mm | World Health Organization (b) moderately controlled patients with diabetes mellitus and 6–8% HbA1c | Immunohistochemistry | DM + PD | All groups showed mild to strong immunoreactivity for RAGE receptor. The patients with T2DM and chronic periodontitis had more BOP, PD, and CAL compared to the control group ( | ||||
| No DM + PD | Six patients showed mild immune reactivity for RAGE. Twelve showed negative immune reactivity for RAGE. | |||||||||
| Male: Female: 1.2: 1.0 | Periodontitis: presence of at minimum 5 sites with ≥4 mm; horizontal alveolar bone loss noted in the radiographs. PD and CAL | DM: HbA1c ≥ 6.5%No DM: HbA1c (4% to 5.9%) | Immunohistochemistry | DM + PD | - | 46.91 b ± 5.57 | 6.8 ± 1.146 | 7.8 ± 1.424 | - | |
|
| 31.42 c ± 7.42 | 5.8 ± 1.832 | 6.6 ± 1.917 | - | ||||||
|
| - | 21.54 ± 1.46 | 5.8 ± 1.832 | 6.6 ± 1.917 | ||||||
|
| DM + PD group: Male:female: 4.33:1.0 Mean age: 59 ± 1.25 years | Generalized, severe, chronic periodontitis: more than 30% of the sites with > 5 mm CAL. | Diabetes patients → | Immunohistochemistry |
| - | Epithelium (AGE%) = 75 (65–80) | 7 (7–7.2) | 6.4 (6.3–6.6) | 2 (1.4–3) |
|
| - | Epithelium (AGE%) =70 | 7.1 | 6.6 | 1.9 | |||||
|
| - | Epithelium (AGE%) = 62.5 | 2.6 | 1.1 | - | |||||
|
| Male/female ratio: 1.22: 1.00 | Periodontitis: >30% of the sites: PD > 4 mm | Not mentioned | Immunohistochemistry |
| Immunohistochemistry showed a 1.3-fold increase in the percentage of AGE deposition in subjects with DM (17%) compared to those without DM (13%). AGE deposition more in the vascular structures, epithelial and connective tissues’ cells. | ||||
|
| ||||||||||
|
| ||||||||||
|
| % of females in each group: No DM + No PD = 17.3; No DM + PD = 15.3; DM + No PD = 33.7; DM + PD = 33.7 | Periodontitis group: BOP ≥10% and interdental CAL at ≥2 non-adjacent teeth with PPD ≥ 4 mm. | Fasting plasma glucose (FPG) ≥126 mg/dL (7.0 mmol/L, and HbA1c ≥ 6.5% (48 mmol/mol) | ELISA |
| AGE: 332 ± 350 ng/mL | - | 5.52 ± 0.53 | 6.29 ± 0.69 | - |
|
| AGE: 235 ± 360 ng/mL | - | 2.31 ± 0.37 | 2.59 ± 0.65 | - | |||||
|
| AGE levels: 46.8 ± 52.1 ng/mL | - | 5.30 ± 0.53 | 5.80 ± 0.72 | - | |||||
|
| AGE levels: 24.4 ± 8.5 ng/mL | - | 2.26 ± 0.38 | 2.67 ± 0.69 | - | |||||
Abbreviations: DM—diabetes mellitus; AGE—advanced glycation end product; RAGE—receptor for advanced glycation end products; sRAGE—soluble receptor for advanced glycation end products; esRAGE—encapsulated receptor for advanced glycation end product; cRAGE—cleaved receptor for advanced glycation end product; GI—gingival index; HbA1c—glycated hemoglobin; BOP—bleeding on probing; PD—pocket depth; CAL—clinical attachment level; ELISA—enzyme-linked immunosorbent assay.
Risk of bias (ROB) assessment using Newcastle–Ottawa Scale (NOS).
| S/No | Author, Year | Selection | Comparability | Outcomes | ROB Scores | ||||
|---|---|---|---|---|---|---|---|---|---|
| Representativeness of the Sample: | Sample Size | Non-Respondents | Ascertainment of the Exposure (Risk Factor): | Comparability of Subjects in Different Outcome Groups Based on Design or Analysis. Confounding Factors Controlled | Assessment of Outcome: | Statistical Test | |||
| 1. | Rajeev et al., 2011 [ | b | b | b | a | b | B | c | 4 |
| 2. | Akram et al., 2020 [ | a | b | a | a | a/b | a | a | 9 |
| 3. | Abbass et al., 2012 [ | a | b | a | a | a | B | a | 7 |
| 4. | Takeda et al., 2006 [ | a | b | a | a | a | b | a | 7 |
| 5. | Katz et al., 2005 [ | a | b | b | b | a/b | b | a | 6 |
| 6. | Singhal et al., 2016 [ | a | b | a | a | a/b | b | a | 6 |
| 7. | Yilmaz et al., 2020 [ | a | a | b | b | a/b | a | a | 7 |
| 8. | Zizzi et al., 2013 [ | a | b | a | b | a/b | b | a | 7 |
| 9. | Hussein and Mohammed (2020) [ | a | b | a | a | b | b | a | 7 |
| 10. | Detzen et al., 2019 [ | a | a | a | a | a/b | A | a | 9 |
| 11. | Kashket et al., 2003 [ | a | a | a | a | b | a | a | 9 |
| 12. | Grimm et al., 2015 [ | b | c | b | b | b | b | b | 4 |
| 13. | Wu et al., 2015 [ | a | b | b | b | a | a | a | 8 |